Zhejiang Int'l Group Co

Zhejiang Int'l Group Co Equity Ratio

The Equity Ratio of Zhejiang Int'l Group Co (000411.SZ) as of Oct 21, 2026 is 30.42 %. In the previous year, Equity Ratio was 31.69 % — a change of -4.00% (lower).

Equity Ratio

30.42 %

YoY

-4.00%

Last updated:

Equity Ratio of Zhejiang Int'l Group Co is 2025 30.42 % . Equity Ratio of Zhejiang Int'l Group Co was 2024 31.69 % . It decreases by -4.00% lower compared to the previous year.

The Zhejiang Int'l Group Co Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
10.35 CNY
Jan 1, 2019
14.09 CNY
Jan 1, 2020
14.76 CNY
Jan 1, 2021
15.48 CNY
Jan 1, 2022
15.83 CNY
Jan 1, 2023
30.58 CNY
Jan 1, 2024
31.69 CNY
Jan 1, 2025
30.42 CNY
The Zhejiang Int'l Group Co Equity Ratio history
YEAREquity RatioYoY
30.42 %-4.00%
31.69 %+3.63%
30.58 %+93.20%
15.83 %+2.24%
15.48 %+4.93%
14.76 %+4.74%
14.09 %+36.17%
10.35 %+11.42%
9.29 %-14.49%
10.86 %-1.32%
11.00 %-5.76%
11.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zhejiang Int'l Group Co Stock analysis

What does Zhejiang Int'l Group Co do? Zhejiang Int'l Group Co., Ltd. generates revenue by wholesaling and retailing pharmaceuticals and medical devices. The company buys products from pharmaceutical manufacturers or suppliers and distributes them to distributors, medical institutions, and pharmacies. It also sells directly to consumers through retail terminals. The firm operates exclusively within Mainland China, serving a broad customer base across the healthcare sector. The business model relies on purchasing products from manufacturers or suppliers, then reselling them through wholesale channels to medical institutions and pharmacies, or via retail terminals to end consumers. This dual-channel approach allows the company to reach both institutional and individual customers without direct manufacturing involvement. Mainland China represents the sole market for all its operations. Zhejiang Int'l Group Co., Ltd. focuses on pharmaceutical and medical device distribution, targeting distributors, medical institutions, and pharmacies as key wholesale clients. Retail sales are directed toward consumers through its own retail terminals. The company does not engage in manufacturing, instead acting as a middleman between producers and end users within the Chinese healthcare market. Zhejiang Int'l Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zhejiang Int'l Group Co stock

Equity Ratio of Zhejiang Int'l Group Co is 30.42 % in 2025.

Equity Ratio of Zhejiang Int'l Group Co changed from 31.69 % to 30.42 %, representing a -4.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Zhejiang Int'l Group Co since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Zhejiang Int'l Group Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Zhejiang Int'l Group Co

All Key Metrics — Zhejiang Int'l Group Co